[go: up one dir, main page]

WO2007011873A3 - Method for treating intraocular neovascular diseases - Google Patents

Method for treating intraocular neovascular diseases Download PDF

Info

Publication number
WO2007011873A3
WO2007011873A3 PCT/US2006/027683 US2006027683W WO2007011873A3 WO 2007011873 A3 WO2007011873 A3 WO 2007011873A3 US 2006027683 W US2006027683 W US 2006027683W WO 2007011873 A3 WO2007011873 A3 WO 2007011873A3
Authority
WO
WIPO (PCT)
Prior art keywords
intraocular neovascular
neovascular diseases
treating intraocular
treating
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/027683
Other languages
French (fr)
Other versions
WO2007011873A2 (en
Inventor
Naveed Shams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of WO2007011873A2 publication Critical patent/WO2007011873A2/en
Publication of WO2007011873A3 publication Critical patent/WO2007011873A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method is provided for administering a therapeutically effective amount of VEGF antagonist to a mammal suffering from, or at risk for, an intraocular neovascular disorder.
PCT/US2006/027683 2005-07-15 2006-07-14 Method for treating intraocular neovascular diseases Ceased WO2007011873A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70012005P 2005-07-15 2005-07-15
US60/700,120 2005-07-15
US77759606P 2006-02-27 2006-02-27
US60/777,596 2006-02-27

Publications (2)

Publication Number Publication Date
WO2007011873A2 WO2007011873A2 (en) 2007-01-25
WO2007011873A3 true WO2007011873A3 (en) 2007-05-10

Family

ID=37568528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/027683 Ceased WO2007011873A2 (en) 2005-07-15 2006-07-14 Method for treating intraocular neovascular diseases

Country Status (1)

Country Link
WO (1) WO2007011873A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI705827B (en) 2014-11-07 2020-10-01 瑞士商諾華公司 Methods for treating ocular diseases
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
MX2020009152A (en) 2018-03-02 2020-11-09 Kodiak Sciences Inc IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF.
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHODS OF TREATING AN EYE DISORDER

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030046A1 (en) * 1995-03-30 1996-10-03 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO2006047325A1 (en) * 2004-10-21 2006-05-04 Genentech, Inc. Method for treating intraocular neovascular diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030046A1 (en) * 1995-03-30 1996-10-03 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO2006047325A1 (en) * 2004-10-21 2006-05-04 Genentech, Inc. Method for treating intraocular neovascular diseases

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US, vol. 110, no. 5, May 2003 (2003-05-01), pages 979 - 986, XP002366840, ISSN: 0161-6420 *
"Anti-VEGF Agents Useful in Age-Related Macular Degeneration", AMERICAN ACADEMY OF OPHTHALMOLOGY, 15 October 2005 (2005-10-15) - 18 October 2005 (2005-10-18), Chicago, XP002414529, Retrieved from the Internet <URL:http://www.rsinewsrxreportingfrom.com/content.asp?myid=40&tid=365> [retrieved on 20070110] *
"EINE MULTIZENTRISCHE, RANDOMISIERTE, DOPPELT MASKIERTE, WIRKSTOFF-KONTROLLIERTE PHASE III STUDIE ZUR WIRKSAMKEIT UND SICHERHEIT VON RHUFAB V2(RANIBIZUMAB) IM VERGLEICH MIT EINER PHOTODYNAMISCHEN VERTEPORFIN-THERAPIE (VISUDYNE ) AN PATIENTEN MIT VORWIEGEND KLASSISCHER SUBFOVEALER NEOVASKULAERER ALTER", INTERNET CITATION, 14 March 2005 (2005-03-14), pages 1 - 2, XP002366841, Retrieved from the Internet <URL:http://www.medizin.uni-koeln.de/kliniken/augenklinik/angiolab/klinisc hestudien/anchor.shtml?print> [retrieved on 20060209] *
"Results From A Phase IIIb Study Showed Patients With Wet AMD Treated With Lucentis Quarterly Experienced A 16-Letter Benefit Over The Controls", MEDICAL NEWS TODAY, 3 June 2006 (2006-06-03), internet, pages 1 - 4, XP002414531, Retrieved from the Internet <URL:http://www.medicalnewstoday.com/printerfriendlynews.php?newsid=44460> [retrieved on 20070110] *
ADAMIS A P ET AL: "INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR PREVENTS RETINAL ISCHEMIA-ASSOCIATED IRIS NEOVASCULARIZATION IN A NONHUMAN PRIMATE", ARCHIVES OF OPHTHALMOLOGY, vol. 114, 1996, pages 66 - 71, XP000574864, ISSN: 0003-9950 *
GENETECH: "Preliminary Phase III Data Show Lucentis Maintained Or Improved Vision In Nearly 95 Percent Of Patients With Wet Age-Related Macular Degeneration", INTERNET CITATION, 23 May 2005 (2005-05-23), South San Francisco, pages 1 - 2, XP002414370, Retrieved from the Internet <URL:http://www.macular.org/news/lucentis.html> [retrieved on 20070110] *
KAISER PETER: "Comparison of Recent AMD Clinical Trials: An Evidence-Based Approach to Treating AMD Patients", MEDSCAPE OPHTHALMOLOGY, vol. 6, no. 1, 19 April 2005 (2005-04-19), XP002414371, Retrieved from the Internet <URL:http://www.medscape.com/viewarticle/503094_print> [retrieved on 20070111] *
KRZYSTOLIK M G ET AL: "PREVENTION OF EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIBODY FRAGMENT", ARCHIVES OF OPHTHALMOLOGY, vol. 120, no. 3, March 2002 (2002-03-01), pages 338 - 346, XP009061383, ISSN: 0003-9950 *
MURAT V. KALAYOGLU: "Emerging Treatment Strategies For Age-Related Macular Degeneration", MEDCOMPARE/OPHTHALMOLOGY, 30 June 2004 (2004-06-30), pages 1 - 2, XP002414528, Retrieved from the Internet <URL:http://www.medcompare.com/spotlight.asp?spotlightid=62> [retrieved on 20070110] *
NICHOLS EARL: "AAO: RANIBIZUMAB(RHUFAB) MAY IMPROVE VISION IN AGE-RELATED MACULAR DEGENERATION", INTERNET CITATION, 24 November 2003 (2003-11-24), XP002366839, Retrieved from the Internet <URL:http://www.pslgroup.com/dg/23f2aa.htm> [retrieved on 20060208] *
NOVARTIS -MEDIA RELEASE: "New data from two leading clinical studies show Lucentis® is first therap to improve vision in patients with wet age-related macular degeneration (AMD)", 18 July 2005 (2005-07-18), pages 1 - 4, XP002414530, Retrieved from the Internet <URL:http://hugin.info/134323/R/1002762/153861.pdf> [retrieved on 20070110] *
ROSENFLED: "An Update on Bevacizumab", REVIEW OF OPHTHALMOLOGY, vol. 12, no. 12, 1 December 2005 (2005-12-01), pages 1 - 5, XP002414532, Retrieved from the Internet <URL:http://www.revophth.com/index.asp?page=1_857.htm> [retrieved on 20070110] *

Also Published As

Publication number Publication date
WO2007011873A2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
EP2319492A3 (en) Method for treating intraocular neovascular diseases
WO2007109749A3 (en) Methods for preventing and treating amyloidogenic diseases
WO2008063932A3 (en) Method for treating age-related macular degeneration
WO2007112352A3 (en) Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
TNSN07312A1 (en) Combination of organic compounds
WO2008134724A3 (en) Methods for administering anti-il-5 antibodies
WO2007112357A3 (en) Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
WO2007087457A3 (en) Combination therapy for the treatment of neovascular disorders
WO2008040774A3 (en) Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats
WO2007130842A3 (en) Combination therapy for diseases involving angiogenesis
WO2010053861A3 (en) Biologically active amides
AU2010279892A8 (en) Humanized anti-amyloid-b oligomer antibody
WO2008021970A3 (en) Treatment of motor neuron disease, including certain neurological disorders, motor neuropathies and chronic inflammatory diseases
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
UY29995A1 (en) USE OF A CB1 ANTAGONIST TO TREAT SECONDARY EFFECTS AND NEGATIVE SYMPTOMS OF CHICHOPHRENIA
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
WO2007011873A3 (en) Method for treating intraocular neovascular diseases
WO2007019153A3 (en) Methods for treating hypertension
WO2007114902A3 (en) Alkylthiobenzylpiperidine compounds
WO2007147868A3 (en) Prevention of muscle atrophy
WO2010039742A3 (en) Methods to reduce b-helper t cells to treat autoimmune diseases
WO2007092436A3 (en) Compounds for treating inflammatory disorders, demyelinating disorders and cancers
WO2007114916A3 (en) Arylbenzylpiperidine compounds
WO2006138372A3 (en) Methods and reagents for the treatment of inflammatory disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06787574

Country of ref document: EP

Kind code of ref document: A2